Uniqure NVQURE
▲ PositiveCapitalrelevance
Company prices upsized $225M public offering, raising capital.
Impact on assets 1
Biotech & Genomic Medicine
Uniqure NVuniQure prices upsized $225 million public offering
3▲1 ▼0Impact / 5
uniQure has priced an upsized underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, expecting aggregate gross proceeds of approximately $225 million before deducting underwriting discounts, commissions, and offering expenses. The offering, which is larger than previously announced, is expected to close on or about June 25, 2026, subject to customary closing conditions. uniQure has also granted the underwriters a 30-day option to purchase up to an additional 741,758 ordinary shares at the public offering price less underwriting discounts and commissions. Leerink Partners, Stifel, Guggenheim Securities, and RBC Capital Markets are acting as joint bookrunning managers, with H.C. Wainwright & Co. as lead manager.
Uniqure NVCompany prices upsized $225M public offering, raising capital.